Absci Corp (ABSI NASDAQ) stock market data APIs
$6.3742
0.72(11.3%)
as of June 5, 2026
Try our APIs with
free plan!
Absci Corp Financial Data Overview
Price chart is built with
Anychart
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Prev. Close
6.3742
Open
7.0926
High
7.1294
Low
6.1804
52 wk Range
2.24-7.39
Market Cap
998 M
Shares Outstanding
156 M
Revenue
1 836 K
EPS
-0.19
Beta
2.457
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Absci Corp (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Absci Corp data using free add-ons & libraries
Get Absci Corp Fundamental Data
Absci Corp Fundamental data includes:
- Net Revenue: 1 836 K
- EBITDA: -116 437 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-19
- EPS/Forecast: -0.172
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Absci Corp News
New
Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...
(RTTNews) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business; Absci, ahead o...
Thursday's ETF Movers: ARKG, TRFK
In trading on Thursday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.5% on the day. Components of that ETF showing particular strength include shares of Absci, up about 15.6...
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036
Key Points Absci uses generative AI to design protein drugs before they are tested in a lab. Partnerships with Merck and Owkin validate Absci's hybrid AI-wet-lab drug platform. Long-term upside with ...
Marvell Stock Climbs After AMD Reveals Surprise Stake
This article first appeared on GuruFocus. Marvell Technology (NASDAQ:MRVL) shares rose about 3% on Wednesday after Advanced Micro Devices (NASDAQ:AMD) disclosed a stake in the chipmaker in a quarterl...
Get Absci Corp fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
